Hutchmed (HCM) said Thursday it completed enrollment for a phase 2 trial in China evaluating fanregratinib in certain patients with intrahepatic cholangiocarcinoma (IHCC), a type of primary bile duct cancer.

The company said the single-arm trial enrolled 87 IHCC patients with fibroblast growth factor receptor 2 fusion/rearrangement, and will assess the drug's efficacy and safety, with the primary endpoint of measuring objective response rate.

Hutchmed expects topline results by late 2025, which could support a new drug application in China if positive, the company said.